Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.

Journal of clinical pharmacology - 1 Apr 2001

Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski P M

Abstract excerpt

Two antidepressants, venlafaxine and fluoxetine, were evaluated in vivo for their effect on cytochrome P450 2D6 (CYP2D6) activity, measured by the ratio of dextromethorphan, a sensitive CYP2D6 marker, to its metabolite dextrorphan (i.e., DM:DT) excreted in urine after DM coadministration. Twenty-eight healthy extensive metabolizers of CYP2D6 received either venlafaxine (37.5 mg bid for 7 days, then 75 mg bid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Cyclohexanols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dextromethorphan

Share to Fluoxetine

Share to Metabolic Clearance Rate

Share to Selective Serotonin Reuptake Inhibitors

Share to Urinalysis

Share to Venlafaxine Hydrochloride

Source

Identifiers

PMID: 11304901
DOI: 10.1177/00912700122010159

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.PMID 11304901Read ↗

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.Semantic proximity Read ↗

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.Semantic proximity Read ↗

Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.Semantic proximity Read ↗

Effect of venlafaxine on imipramine metabolism.Semantic proximity Read ↗

Inhibition by fluoxetine of cytochrome P450 2D6 activity.Semantic proximity Read ↗

CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication.Semantic proximity Read ↗

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.Semantic proximity Read ↗

Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.Semantic proximity Read ↗

Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.Semantic proximity Read ↗

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.Semantic proximity Read ↗

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.Semantic proximity Read ↗

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.